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Diverse Osteoclastogenesis of Bone
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Background: Mandibles (MB) andmaxillae possess unique
metabolic and functional properties and demonstrate discrete
responses to homeostatic, mechanical, hormonal, and devel-
opmental stimuli. Osteogenic potential of bone marrow stro-
mal cells (BMSCs) differs between MB versus long bones
(LB). Furthermore, MB- versus LB-derived osteoclasts (OCs)
have disparate functional properties. This study explores the
osteoclastogenic potential of rat MB versus LB marrow
in vitro and in vivo under basal and stimulated conditions.
Methods: Bone marrow from rat MB and LB was cultured
in osteoblastic or osteoclastic differentiation media. Tartrate-
resistant acid phosphatase (TRAP) staining, resorption pit
assays, and real-time polymerase chain reaction were per-
formed. Additionally, osmotic mini-pumps were implanted
in animals, mandibles and tibiae were isolated, and multinu-
cleated cells (MNCs) were measured.
Results: MB versus LBmarrow cultures that were differenti-
ated with receptor activator of nuclear factor-kB ligand
(RANKL) andmacrophage colony-stimulating factor produced
more TRAP+ MNCs and greater resorptive area. To explore
MB versus LB BMSC-supported osteoclastogenesis, confluent
BMSCs were cultured with parathyroid hormone (PTH),
1,25-dihydroxyvitamin D3 (1,25D3), or PTH+1,25D3. 1,25D3-
or PTH+1,25D3-treated LB BMSCs expressed significantly
higher RANKL and lower osteoprotegerin (OPG) mRNA and
increased RANKL:OPG ratio. When whole marrow was cultured
with PTH+1,25D3, more TRAP+ MNCs were seen in LB versus
MB cultures. Ultimately, rats were infused with PTH+1,25D3,
and MB versus tibia MNCs were measured. Hormonal stimula-
tion increased osteoclastogenesis in both MB and tibiae. How-
ever, higher TRAP+ MNC numbers were observed in tibiae
versus MB under basal and hormonal stimulation.
Conclusion: Collectively, these data illustrate differences of
both osteoclastogenic potential and OC numbers of MB versus
LB marrow. J Periodontol 2014;85:829-836.
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S
imilar to other craniofacial bones,
the mandible (MB) and maxilla
display developmental, functional,
and homeostatic properties distinct from
the appendicular skeleton. The jaws
arise from neural crest cells of neuro-
ectoderm rather than mesoderm1 and
are formed primarily by intramem-
branous as opposed to endochondral
ossification.2 1,25-dihydroxyvitamin D3
(1,25D3) and parathyroid hormone
(PTH) knockout mice demonstrate that
MB mineralization is affected by 1,25D3
deficiency but remains unaltered by
abolishment of PTH. In contrast, long
bones (LB) show effects in loss of both
hormones.3 Similarly, in ovariectomized
and malnutrition rodent models, the MB
loses significantly less bone than the
proximal tibia.4 Skeletal diseases only
affecting the jaws, such as periodontitis,5
cherubism,6 hyperparathyroid jaw tumor
syndrome,7 and bisphosphonate-related
osteonecrosis of the jaws (ONJ),8 further
support distinctive MB homeostasis.
An increased osteogenic potential of
rodent and human MB versus LB bone
marrowstromalcells(BMSCs)bothinvitro
and in vivo has been described.9-11 Fur-
thermore, human mandibular or maxil-
lary BMSCs show enhanced response to
osteogenic differentiation factors and
bone morphogenetic protein 2 compared
with cells derived from iliac crest.10,11
Osteoclasts (OCs) are multinucleated,
bone-resorbing cells whose differentiation
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and maturation requires macrophage colony-
stimulating factor (M-CSF) and receptor activator of
nuclear factor-kB ligand (RANKL), which are among
the cytokines supplied by BMSCs.12 Bone site–
specific phenotypic and functional differences of
osteoclasts have been proposed.13 OCs from calvariae
versus LB show differential usage of proteinases14,15
and expression levels of the enzyme tartrate-resistant
acid phosphatase (TRAP).15,16 In addition, murine jaw
and LB marrows have different osteoclastic potential in
the presence of M-CSF and RANKL stimulation and
exhibit distinctive shape and response to culturing
substrates.17,18
BMSCs are important regulators of osteoclasto-
genesis. BMSCs produce osteoprotegerin (OPG), an
osteoclast decoy receptor that competes with RANK
for RANKL binding.19 Therefore, the RANKL:OPG
ratio pivotally determines the direction of osteo-
clastogenesis. RANKL and OPG expression is mod-
ulated by local cytokines and systemic hormones
such as PTH and 1,25D3.20,21 Interestingly, the basal
RANKL:OPG ratio is higher in mouse jaw versus LB
cultures, suggesting differential ability of the marrow
environment to support osteoclastogenesis.18 How-
ever, differential ability of MB versus LB BMSCs to
support osteoclastogenesis in stimulated conditions
is not well understood.
The authors hypothesize that the jaws have distinct
basal and induced osteoclastogenic potential com-
pared with the other skeletal sites. Such differential
osteoclastogenic response could underlie, at least in
part, the pathophysiologic mechanisms of diseases
unique to the jaws. This study explores the osteo-
clastogenic potential of rat MB versus LB marrow
in vitro and in vivo under basal and hormone treat-
ment. To the best of the authors’ knowledge, this is
the first report investigating MB marrow osteoclas-
togenesis under stimulated conditions. These data
support differences of both osteoclastogenic poten-
tial and OC numbers of MB versus LB marrow.
MATERIALS AND METHODS
Isolation and Culture of Mandible and LB Marrow
Cells
Animal approval and surgical procedures conformed
to guidelines by the University of California–Los
Angeles Chancellor’s Animal Research Committee.
MB and LBmarrow cells were isolated from 1-month-
old male Sprague-Dawley rats,§ as previously de-
scribed.9 Harvested whole marrow was pooled in
a single suspension, and red blood cells were lysed by
red blood cell lysis solution.i
For BMSC cultures, cells were cultured at a density
of 1 · 106 cells/mL (5.3 · 105cells/cm2) in a-minimal
essential medium (a-MEM)¶ supplemented with 10%
FBS and 1% antibiotics (100 U/mL penicillin and 100
mg/mL streptomycin). After 6 days and upon con-
fluence, suspension cells were discarded. Adherent
BMSCs were cultured in fresh osteogenic differenti-
ation medium (a-MEM + 10% FBS with 50 mg/mL
ascorbic acid and 4 mM b-glycerophosphate) with
the addition of vehicle, PTH (10 nM), or 1,25D3 (10
nM), which was replaced every 3 to 4 days. For whole
marrow experiments, cells were cultured without the
removal of suspension cells, and half of the media
were replaced every 3 to 4 days.
Osteoclastogenesis
Bone marrow cell suspensions in media supple-
mented with 25 ng/mL rat M-CSF# were plated in
100-mm culture dishes overnight. Non-adherent
cells were plated at 1.5 · 105 cells/100mL in osteo-
clastogenic medium (a-MEM + 10% FBS, 50 ng/mL
M-CSF, 80 ng/mL sRANKL),** which was replaced
every 2 to 3 days. After 6 days, cells were fixed and
stained for TRAP activity using the leukocyte acid
phosphatase kit. TRAP+ multinucleated cells (‡3
nuclei) were counted under light microscope.
Bone Resorption Assay
Osteoclast precursors were cultured on calcium
phosphate–coated 16-well plates†† in a-MEM alone
or osteoclastogenic media. After 10 days, cells were
removed, and total resorption pit area was visualized
by von Kossa stain. Using a light microscope camera,
an image of each well was captured at ·2 magnifi-
cation. The total resorbed area of each well was
measured using imaging software.‡‡
RNA Isolation and Real-Time Quantitative
Polymerase Chain Reaction
Total RNA fromBMSC culture was collected at days 7
and 14, peak osteogenic potential time points pre-
viously described,9 using reagent,§§ and used for
quantitative polymerase chain reaction (PCR), per-
formed in triplicate for at least three independent
experiments, with PCR mixii and rat gene–specific





ACACTCG-39 (reverse); and GAPDH (NM_017008)
59-TTCAACGGCACAGTCAAGG-39 (forward), 59-AT-
ACTCAGCACCAGCATCAC-39 (reverse). The maxi-
mum gene expression normalized to GAPDH was set
§ Charles River, Wilmington, MA.
i BioLegend, San Diego, CA.
¶ Mediatech, Herndon, VA.
# PeproTech, Rocky Hill, NJ.
** Sigma-Aldrich, St. Louis, MO.
†† BioCoat Osteologic MultiTest Slides, BD Biosciences, Bedford, MA.
‡‡ CellSens, Olympus, Center Valley, PA.
§§ Trizol, Invitrogen, Carlsbad, CA.
ii iQ SYBR Green supermix, Bio-Rad, Hercules, CA.
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at 100%, and the remaining expression levels were
calculated as percentage of maximum induction. The
authors elected to express gene levels as percentage
of maximum instead of fold change to avoid large
and artificial fluctuations of gene induction in cases
where control levels were low.
In Vivo Assessment of Osteoclastogenesis
Eight male 3-month-old Sprague-Dawley rats were
used. Subcutaneously implanted mini-osmotic pumps¶¶
continuously infused vehicle or 40 mg/kg/day human
PTH (1-34)## and 2 mg/kg/day 1,25D3*** for 3 days.
This timing of PTH and 1,25D3 treatment has shown
peak osteoclastic induction in vivo.22,23 Animals
were sacrificed at day 4, and MB and tibiae were fixed
in 4% formaldehyde solution for 48 hours and stored
in 70% ethanol.
Bones were decalcified in 14.5% EDTA (pH 7.2)
for 4 weeks. Paraffin-embedded 4-mm-thick coronal
sections at the interproximal area between the first
and second mandibular molars and cross sections of
proximal tibiae were stained with hematoxylin and
eosin (H&E) and digitally scanned using an auto-
mated slide scanner††† and software.‡‡‡ Osteoclasts
(‡2 nuclei represent multinucleation, distinguishing
from mononucleated preosteoclasts24) in contact
with the bone surface and bone area were measured
(software annotation tool) within the alveolar bone
region of themandible and the trabecular bone region
of the proximal tibia.
Statistical Analyses
Data were expressed as mean – SEM from at least
three independent experiments. Data among groups
were compared with one-way analysis of variance,
and statistical differences among groups were iden-
tified using Student t test. P <0.05 was considered
significant.
RESULTS
Higher Number of TRAP+ Multinucleated Cells
and Increased Resorption of MB Versus LB
Marrow
To study the differences between the osteoclasto-
genic potential of rat MB versus LB marrow, non-
adherent marrow cells were differentiated intomature
OCs by M-CSF and RANKL. At day 6 of culture,
TRAP+ multinucleated cells (MNCs) were observed in
both MB and LB cultures (white arrows, Figs. 1A and
1B). However, significantly more TRAP+ MNCs were
seen in MB cultures (Fig. 1C). To verify that the
observed TRAP+ MNCs were functional osteoclasts,
osteoclast precursors were differentiated on calcium
phosphate substrates. MB cultures showed increased
resorptive pit formation (Figs. 1D and 1E) with sig-
nificantly higher total resorbed area (Fig. 1F) than
the LB cultures.
MB Versus LB BMSCs Possess a Lower
Osteoclastogenic Potential Under Hormonal
Stimulation
BMSCs support osteoclastogenesis through modu-
lation of the RANKL-OPG system. Hormones that
regulate bone homeostasis, such as PTH and 1,25D3,
regulate production of osteoclast regulatory cyto-
kines.21,25 The authors thus explored RANKL and
OPG expression in basal and hormone-stimulated
conditions at 7 and 14 days of rat MB versus LB
BMSC cultures. Basal RANKL and OPG mRNA ex-
pression was similar in MB versus LB BMSCs (Figs.
2A and 2B). However, in the presence of 1,25D3
alone or in combination with PTH, RANKL expression
was higher in LB versus MB cultures at both 7
(P <0.05) and 14 (P <0.01) days (Fig. 2A). Under
the same treatments, the inhibition of OPG expres-
sion was greater in LB versus MB BMSCs with
PTH+1,25D3 (P <0.01) and 1,25D3 alone (P <0.05) at
day 14 (Fig. 2B). Importantly, the RANKL:OPG ratio
was substantially enhanced in LB versus MB BMSCs
under 1,25D3 alone or in combination with PTH at
7 and 14 days of culture (Fig. 2C).
LB Versus MB Whole Marrow Generates More
TRAP+ MNCs Under Hormonal Induction
These data showed that although rat MB marrow has
a higher osteoclastogenic potential in the presence
of M-CSF and RANKL, hormonally stimulated LB
BMSCs express higher levels of RANKL and RANKL:
OPG ratio that would favor increased osteoclasto-
genesis. To evaluate the osteoclastogenic ability of
rat MB versus LB marrow, the authors cultured whole
marrow under basal and PTH+1,25D3 treatment.
TRAP staining revealed TRAP+ MNCs in both LB and
MB culture under PTH+1,25D3 stimulation but not at
baseline (Fig. 3A). Quantitatively, LB marrow cul-
tures contained significantly more TRAP+ MNCs
compared with MB culture (Fig. 3B).
Higher Basal and PTH+1,25D3-Stimulated MNC
Number in Tibia Versus Mandible in Rats In Vivo
To evaluate basal and hormonal stimulation of os-
teoclast formation in vivo, mini-osmotic pumps
containing either vehicle or PTH+1,25D3 were sub-
cutaneously implanted for 3 days in adult rats. Then
MB and tibiae were decalcified, and H&E staining was
performed on sections from the trabecular bone of
the proximal tibia metaphyseal area (Figs. 4A
through 4C) and the mandibular alveolar bone in the
interproximal area between the first and second
molars (Figs. 4D through 4F). MNCs abutting the
¶¶ Alzet model 1003D, Alza, Palo Alto, CA.
## Bachem, Torrance, CA.
*** Sigma-Aldrich.
††† Aperio XT, Aperio Technologies, Vista, CA.
‡‡‡ Aperio Imagescope v.11, Aperio Technologies.
J Periodontol • June 2014 Chaichanasakul, Kang, Bezouglaia, Aghaloo, Tetradis
831
bone, presumably representing osteoclasts, were
observed at baseline and under PTH+1,25D3 stimu-
lation in both tibia and MB (Figs. 4B, 4C, 4E, and 4F,
green arrows). At baseline, more osteoclasts were
observed in tibia versus MB. PTH+1,25D3 signifi-
cantly increased osteoclast numbers in both tibia and
MB. Importantly, greater numbers of MNCs were
observed under hormonal stimulation in tibia com-
pared with MB (Fig. 4G).
DISCUSSION
Mandible, a bone of the orofacial complex, possesses
unique metabolic and functional properties and
demonstrates discrete responses to homeostatic,
mechanical, and developmental stimuli.26 Bone
diseases such as cherubism,6 hyperparathyroid jaw
tumor syndrome,7 and ONJ8,27,28 affect the jaws
while sparing the remaining skeleton. Differences in
the osteogenic potential of LB versus MB BMSCs
suggest a skeletal site–specific BMSC response to
various stimuli during bone remodeling and heal-
ing.10,29 This study examines potential differences in
the osteoclastogenic ability between MB and LB
under basal and stimulated conditions. Exploring
mandibular osteoclastogenic potential under basal
and hormonal regulation is significant, since it would
provide valuable understanding of jawbone homeo-
stasis and might lead to better target approaches for
bone conditions that selectively affect the face.
The authors first investigated the in vitro potential
of rat MB versus LB marrow cells to form osteoclasts
in the presence of M-CSF and
RANKL. MB marrow generated
significantly more TRAP+ MNCs.
The authors tested marrow os-
teoclastogenesis at 6 days
of culture.30 To test whether
differences in TRAP+ MNC
numbers result in increased
resorption, the authors used
a calcium phosphate substrate
as a neutral culturing surface.
Increased osteoclast forma-
tion was mirrored by larger
total resorbed area generated
by MB osteoclasts in com-
parison to LB cultures. The
findings suggested an increased
osteoclastic potential of MB
marrow.
Previous reports utilizing
mouse-derived MB and LB
marrow found higher osteoclast
numbers in LB marrow cultures
at earlier time points, although
at later time points no differ-
ence was observed. A difference in the MB versus LB
marrow cellular composition, with monocytes and
myeloid blasts as principal cells in the jaw and LB,
respectively, could have accounted for the observed
difference at the earlier time points.18 Interestingly,
differences in osteoclast number between MB and
LB appear to depend on the substrate the cells are
cultured on. More osteoclasts were observed in LB
marrow when cells were cultured in plastic or bone
slices, while the contrary was true when cells were
cultured on dentin slices.17 Utilization of rats versus
mice as well as experimental differences in preparing
and culturing marrow cells could account for the
disparate findings in this study, where the authors
observed differences in osteoclastogenic potential
between the two skeletal sites, and other studies,
where no differences were observed.18
Because the authors observed a higher osteo-
clastic potential of rat MB marrow when M-CSF and
RANKL was added to the culture, they sought to
investigate whether there is a difference in the ability
of MB versus LB BMSCs to support osteoclast for-
mation. Such differences should not be surprising,
since diverse function of BMSCs from various skeletal
sites, including the jaws, have been reported for
humans and rodents.9,10,31 BMSCs can support os-
teoclastogenesis through the production of RANKL
and OPG. Furthermore, systemic hormones such as
PTH and 1,25D3 induce osteoclast formation by,
among others, altering RANKL and OPG expression
and thus regulating the RANKL:OPG ratio.20,21,32
Figure 1.
TRAP staining of cultures from LB (A) and MB (B) after 6 days of differentiation with M-CSF and RANKL.
TRAP+MNCs (indicated bywhite arrows) are shown at·4magnification.C)Quantification of total TRAP+
MNCs (>3 nuclei) formed by LB and MB marrow after 6 days of differentiation (mean – SEM). Von
Kossa stain reveals resorptive pits formed by LB (D) and MB (E) marrow cultures after 10 days of
differentiation in the presence of M-CSF and RANKL on calcium phosphate substrate. F) Quantification
of total resorbed area formed in LB and MB cultures (mean – SEM). *P <0.05.
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1,25D3, alone or in combination with PTH, induced
RANKL expression in both MB and LB BMSCs.
However, the RANKL induction in LB cells was sig-
nificantly greater than that in MB cells. PTH, 1,25D3,
and PTH+1,25D3 significantly attenuated OPG ex-
pression in LB BMSCs. Only PTH+1,25D3 inhibited
OPG expression in MB BMSCs at 14 days of culture.
Importantly, the inhibition of OPG expression in LB
BMSCs was more pronounced. This differential
RANKL induction and OPG inhibition resulted in an
elevated RANKL:OPG ratio of LB BMSCs under stim-
ulated conditions, suggesting a disparate response of
LB versus MB BMSCs to hormonal stimulation.
The ability of cells along the osteoblastic lineage to
support osteoclastogenesis has been explored.33 Al-
though immature versus differentiated osteoblasts
exhibit a strong potential to support osteoclast for-
mation and differentiation in vitro,34 the vital role of
osteocytes in regulation of osteoclast formation in
vivo at baseline, as well as during unloading, is well
established.35,36 In these experiments, the authors
studied RANKL and OPG expression at two culture
points, representing different osteoblastic potential of
marrow stromal cells.9 Basal RANKL levels were higher
at later time points of culture, suggesting increased
ability for support of osteoclastogenesis of more dif-
ferentiated stromal cells. However, PTH and 1,25D3
induced RANKL at a similar level for all time points.
Osteoclast formation depends on the availability of
osteoclastic precursors, as well as on appropriate
signals that will promote their differentiation and
fusion into mature multinucleated osteoclasts. To
compare the ability of rat LB versus MB marrow to
form MNC TRAP+ cells, whole marrow in the absence
of added RANKL and M-CSF was cultured in the
presence of hormonal stimulation. LB marrow gen-
erated significantly greater TRAP+ MNCs, reinforcing
the higher osteoclastogenic ability of LB marrow
under PTH+1,25D3 treatment. Ultimately the authors
evaluated basal and hormonal stimulation of osteo-
clast formation in vivo. Interestingly, higher MNC
numbers were identified in tibiae versus MB in control
animals, indicating that baseline bone homeostasis
favors increased osteoclast presence that might
reflect higher basal bone remodeling in long bones.
Hormonal treatment significantly induced osteoclast
formation in both skeletal sites with a higher overall
osteoclast number in tibiae, similar to the in vitro find-
ings of PTH+1,25D3 increase in whole marrow MNCs.
Overall, the authors detected distinct osteoclas-
togenic ability of rat MB versus LB marrow. MB
marrow appeared to posses more basal osteoclast
precursors. Alternatively MB pre-osteoclasts could
demonstrate increased proliferation under M-CSF
and RANKL stimulation. However, LB marrow cells
responded to hormonal treatment with enhanced
RANKL gene expression and RANKL:OPG ratio, and
with increased osteoclast numbers. These observa-
tions point to discrete and complex regulation of jaw
versus appendicular bone homeostasis. These find-
ings have potential implications for pharmacologic
treatment of periodontal bone loss. Osteoclast acti-
vation is central in the pathogenesis of peri-
odontitis.37-39 Pharmacologic inhibitors of osteoclast
function or differentiation attenuate bone loss in
animal models of periodontitis and have been en-
tertained as potential interventions for periodontal
Figure 2.
Effect of PTH (10 nM) and 1,25D3 (10 nM), alone or in combination, on
the expression of RANKL (A), OPG (B), and RANKL:OPG ratio (C) by LB
versus MB BMSCs cultured in osteogenic media for 7 or 14 days. mRNA
levels were normalized to GAPDH and expressed as percentage of
maximum expression (mean – SEM). For control, vehicle-treated BMSCs
were cultured in osteogenic media for 7 or 14 days. *P <0.05; †P <0.01.
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disease.40-45 Systemic hormones and inflammatory
cytokines play key roles in osteoclast formation and
activation.38,43,46,47 Indeed, association of systemic
diseases that show increased osteoclast activity
with periodontal bone loss has been explored.48-51
These results suggest a bone site–specific regulation
of osteoclast activation. Combined with other pub-
lished data that show bone site–specific differences
in osteoclastic function,13,14,17 potential specific in-
hibitors of alveolar bone osteoclast activation and/or
function could be developed. Such pharmacologic
interventions would be important in regulating peri-
odontal bone loss, while sparing bone homeostasis in
the remainder of the skeleton. Alternatively, osteo-
clastic inhibitors for the rest of the skeleton but not
the jaws would be valuable for management of bone
metabolic diseases, such as osteoporosis or bone
cancer, while reducing the risk for ONJ.
CONCLUSIONS
In summary, these data demonstrate a diverse os-
teoclastogenic capacity of rat MB versus LB marrow.
Figure 3.
A) TRAP staining of LB versus MB whole marrow under control or PTH+1,25D3 treatment after 7 days. (Original magnification ·4X.) B) Quantification
of TRAP+ MNC numbers in LB or MB marrow cultures (mean – SEM). *P <0.05 compared with vehicle-treated control; †P <0.05 compared with
PTH+1,25D3-treated group.
Figure 4.
H&E-stained sections of tibia (A through C) and MB (D through F) at ·2 (A, D) and ·40 (B, C, E, F) magnification. Sprague-Dawley rats were
continuously infusedwith vehicle (B andE) or PTH+ 1,25D3 (Cand F) for 3 days.G)MNCsabutting bone surface (indicated by green arrows in B, C, E, and F)
were measured within the trabecular bone of tibia and MB (black rectangular outline, A and D). N.Oc/B.Pm = number of osteoclasts per bone perimeter.
*P <0.05 compared with vehicle-treated control; †P <0.05 compared with MB.
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Although MB marrow appeared to possess intrinsi-
cally more osteoclast precursors, LB BMSCs showed
enhanced response to hormonal increase of RANKL
expression and RANKL:OPG ratio. Furthermore, PTH
and 1,25D3 induced higher TRAP+ MNC numbers in
whole marrow of LB versus MB. Paralleling these
findings, tibiae showedhigher osteoclasts at basal and
PTH+1,25D3-stimulated conditions. The diverse os-
teoclastic potential of the MB versus other skeletal
sites could explain, in part, the differential response of
the jaws to mechanical, hormonal, and nutritional
signals, as well as to antiresorptive therapies.
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